BioCardia, Inc. — Form 8-K
Filed October 7, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
BioCardia announced presentation of CardiAMP HF II trial design at Heart Failure Society of America Annual Scientific Meeting (October 9–12, 2026 in Phoenix). The trial evaluates high-dose autologous cell therapy for ischemic heart failure patients with reduced ejection fraction. FDA has agreed the ongoing CardiAMP HF II trial may be sufficient to support FDA approval; no new financial data, partnerships, or material agreements disclosed.
Why this rating
Conference presentation is routine clinical-stage disclosure. No financing, partnership, trial results, or regulatory decision announced. Milestone is procedural, not material to $9.7M market-cap company.
See more from October 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.